Concomitant High Apoptosis Inhibitor of Macrophage (AIM) and Low Prostate-Specific Antigen (PSA) Indicates Activated T Cell-Mediated Anticancer Immunity, Enhance Sensitivity to Pembrolizumab, and Elicit Good Prognosis in Prostate Cancer

Background: Despite its widespread use, the use of prostate-specific antigen (PSA) alone as a screening biomarker for prostate cancer (PCa) leads often to unwarranted prostate biopsy, over-diagnosis, and consequently, over-treatment, because of its limited specificity. There are reports that the apo...

Descripción completa

Detalles Bibliográficos
Autores principales: Bamodu, Oluwaseun Adebayo, Wang, Yuan-Hung, Yeh, Chi-Tai, Ho, Chen-Hsun, Chiang, Yi-Te, Kao, Wei-Tang, Liu, Chia-Hung, Wu, Chia-Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469063/
https://www.ncbi.nlm.nih.gov/pubmed/34572412
http://dx.doi.org/10.3390/biomedicines9091225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469063/
https://www.ncbi.nlm.nih.gov/pubmed/34572412
http://dx.doi.org/10.3390/biomedicines9091225

Ejemplares similares